The Department of Pharmaceuticals (DoP) has rejected the Mumbai-based pharmaceutical company Ajanta Pharmaceuticals' review application against fixation of retail price of tramodol+diclofenac SR tablets.
In its order dated October 10, the DoP, after examining the review application filed by Ajanta Pharmaceuticals against the fixation of retail price of tramodol+diclofenac SR tablets, said that the application of the petitioners is rejected because there was no merit in the application.
Earlier, the National Pharmaceutical Pricing Authority (NPPA), vide price fixation Order S.O. No.2102 (E) dated 20.8.2014, had fixed retail price of tramodol+diclofenac SR tablets under DPCO, 2013.
Aggrieved by the notification, Ajanta had represented to the reviewing authority DoP against the NPPA notification.
Acting on Ajanta Pharmaceuticals' representation, personal hearing was granted to the petitioners by the DoP on 16.9.2014. The petitioners were represented by Arvind K Agrawal, CFO and Satish Agrawal, executive vice president. On behalf of the NPPA, Naresh Arya, deputy director attended the hearing.
The issues involved in the review application have been examined based on the record note of discussions of the personal hearing, other documents on record and the DoP ordered, “The application of the Petitioners is rejected having no merit.”